Document is current
Any future updates will be listed below
-
Authors
Suchy, Fabian P. http://orcid.org/0000-0002-7187-5360
Karigane, Daiki http://orcid.org/0000-0002-4017-5193
Nakauchi, Yusuke http://orcid.org/0000-0002-6943-3811
Higuchi, Maimi
Zhang, Jinyu
Pekrun, Katja http://orcid.org/0000-0001-8346-1889
Hsu, Ian http://orcid.org/0000-0002-1648-5060
Fan, Amy C. http://orcid.org/0000-0003-1612-1862
Nishimura, Toshinobu http://orcid.org/0000-0002-5425-1708
Charlesworth, Carsten T.
Bhadury, Joydeep http://orcid.org/0000-0002-4333-9974
Nishimura, Toshiya
Wilkinson, Adam C. http://orcid.org/0000-0001-7406-0151
Kay, Mark A. http://orcid.org/0000-0002-2799-2615
Majeti, Ravindra http://orcid.org/0000-0002-5814-0984
Nakauchi, Hiromitsu http://orcid.org/0000-0002-9841-6973
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 8 February 2024
First Online: 8 April 2024
Competing interests
: R.M. is on the advisory boards of Kodikaz Therapeutic Solutions, Orbital Therapeutics, Pheast Therapeutics and 858 Therapeutics. R.M. is a co-founder of and equity holder in Pheast Therapeutics, MyeloGene and Orbital Therapeutics. H.N. is a co-founder of and shareholder in Megakaryon, Century Therapeutics and Celaid Therapeutics. The remaining authors declare no competing interests.
